Evaluating CMV Infection and Reactivation after Emapalumab: A Retrospective Evaluation of Letermovir Prophylaxis

Puntos clave

• CMV infection and reactivation were significantly assessed after initiating letermovir prophylaxis, showing variable outcomes.
• The evaluation revealed a notable rate of CMV reactivation in patients receiving emapalumab alongside letermovir.
• Analysis incorporated retrospective evaluation methods, providing insights into the efficacy of prophylaxis in preventing CMV complications.
• These findings highlight the need for further investigation into CMV management protocols among patients at risk.